產(chǎn)品詳情
簡單介紹：
重組人血管抑素蛋白與其它公司提供的重組蛋白不同，rHuAngiostatin蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人血管抑素蛋白（全長序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測、ELISA等試驗(yàn)中.
詳情介紹：
重組人血管抑素蛋白
| Species | Human |
| Accession | P00747 |
| GeneID | 5340 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人血管抑素蛋白Approximately 29.7 KDa, a single non-glycosylated polypeptide chain containing 259 amino acids. |
| Quantity | 10μg/50μg/1000μg |
| AA Sequence | VYLSECKTGN GKNYRGTMSK TKNGITCQKW SSTSPHRPRF SPATHPSEGL EENYCRNPDN DPQGPWCYTT DPEKRYDYCD ILECEEECMH CSGENYDGKI SKTMSGLECQ AWDSQSPHAH GYIPSKFPNK NLKKNYCRNP DRELRPWCFT TDPNKRWELC DIPRCTTPPP SSGPTYQCLK GTGENYRGNV AVTVSGHTCQ HWSAQTPHTH NRTPENFPCK NLDENYCRNP DGKRAPWCHT TNSQVRWEYC KIPSCDSSP |
| Purity | 重組人血管抑素蛋白> 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The specific activity determined by an assay on anti-proliferation and anti-migration using endothelial cells in vitro and anti-angiogenesis in vivo is 5.5 × 105 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM NaAc, pH 5.5, 4 % mannitol. |
| Endotoxin | Less than 1 EU/μg of rHuAngiostatin as determined by LAL method. |
| Reconstitution | 重組人血管抑素蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人血管抑素蛋白 | |
| Reference |
1. Takahashi S, Shinya T, Sugiyama A. 2010. J Pharmacol Sci, 112: 432-7. 2. Frank KFandMuller-Ehmsen J. 2009. Heart, 95: 269-70. 3. Perri SR, Annabi B, Galipeau J. 2007. FASEB J, 21: 3928-36. 4. Kim KS, Kim HS, Park JS, et al. 2004. Cancer Gene Ther, 11: 441-9. 5. Wahl ML, Owen CS, Grant DS. 2002. Endothelium, 9: 205-16. |
| Background | Angiostatin, is a ~30 kDa fragment of plasminogen that is encoded by the PLG gene in humans. It is produced, for example, by autoproteolytic cleavage of plasminogen, involving extracellular disulfide bond reduction by phosphoglycerate kinase. Furthermore, angiostatin can be cleaved from plasminogen by different metalloproteinases (MMPs), elastase, prostate-specific antigen (PSA), 13 kDa serine protease, or 24 kDa endopeptidase. Angiostatin is known to bind many proteins, especially to angiomotin and endothelial cell surface ATP synthase but also integrins, annexin II, C-met receptor, NG2 proteoglycan, tissue-type plasminogen activator, chondroitin sulfate proteoglycans, and CD26. It seems to involve inhibition of endothelial cell migration, proliferation and induction of apoptosis, but its mechanism of action is still unclear. Angiostatin is currently undergoing clinical trials for its use in anticancer therapy. Recombinant angiostatin is expressed in E. coli. |
